Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Regenxbio (RGNX) over the last 9 years, with Q3 2025 value amounting to $2.9 million.

  • Regenxbio's Treasury Shares rose 4270.27% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 4270.27%. This contributed to the annual value of $2.0 million for FY2024, which is 5599.69% up from last year.
  • According to the latest figures from Q3 2025, Regenxbio's Treasury Shares is $2.9 million, which was up 4270.27% from $3.0 million recorded in Q2 2025.
  • Regenxbio's Treasury Shares' 5-year high stood at $3.0 million during Q2 2025, with a 5-year trough of $254000.0 in Q1 2021.
  • For the 5-year period, Regenxbio's Treasury Shares averaged around $1.3 million, with its median value being $1.4 million (2023).
  • In the last 5 years, Regenxbio's Treasury Shares skyrocketed by 20042.46% in 2023 and then surged by 1713.48% in 2024.
  • Regenxbio's Treasury Shares (Quarter) stood at $277000.0 in 2021, then skyrocketed by 121.3% to $613000.0 in 2022, then surged by 113.54% to $1.3 million in 2023, then skyrocketed by 56.0% to $2.0 million in 2024, then soared by 42.21% to $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q3 2025, $3.0 million for Q2 2025, and $2.3 million during Q1 2025.